SUMMARy
The development of effective cryopreservation techniques for both red blood cells and platelets, which maintain ex vivo biological activity, in combination with frozen plasma, provides for a unique blood banking strategy. This technology greatly enhances the storage life of these products. The rationale and potential advantages of using cryopreservation techniques for the provision of blood products to remote and military environments have been effectively demonstrated in several conflicts over the last decade. Current haemostatic resuscitation doctrine for the exsanguinating patient supports the use of red blood cells, platelets and frozen plasma early in the resuscitation. We believe an integrated fresh-frozen blood bank inventory could facilitate provision of blood products, not only in the military setting but also in regional Australia, by overcoming many logistic and geographical challenges. The processes involved in production and point of care thawing are sufficiently well developed and achievable to make this technology a viable option. The potential limitations of cryopreservation and subsequent product thawing need to be considered if such a strategy is to be developed. A substantial body of international experience using cryopreserved products in remote settings has already been accrued. This experience provides a template for the possible creation of an Australian integrated fresh-frozen blood bank inventory that could conceivably enhance the care of patients in both regional Australia and in the military setting.
Cryopreserved blood produCts
Anaesthesia and Intensive Care, Vol. 41, No. 1, January 2013 with RBCs, plasma and platelets thus restoring volume, RBC oxygen-carrying capacity, plasmaborne coagulation factors and thrombus-generating platelets [18] [19] [20] [21] [22] [23] . If early blood product provision in severe haemorrhage is accepted as the standard of care, then the issue of how these products are provided and reliably resupplied in remote or austere environments requires careful consideration. Storage and transport of frozen RBCs, platelets and plasma at -80°C provides a very attractive option to address this problem. This review will focus on methods currently employed to produce deep frozen blood products, the practicalities associated with their use and potential limitations.
OPTIONS FOR BLOOD PRODUCT PROVIS-ION IN THE TREATMENT OF SIGNIFICANT HAEMORRHAGE
Traditionally there have been two methods of providing blood products to austere or remote environments; the first is continual resupply with refrigerated packed RBCs, room temperature platelets and frozen plasma from central organisations such as the Australian Red Cross Blood Service. This approach is limited by the shelf life of these products and hence the need for frequent resupply 24 . In Australia, refrigerated standard liquid RBCs have a maximum shelf life of 42 days and standard liquid platelets have a maximum shelf life of five days 25 . This precludes their use in maritime, military or remote environments, thereby preventing the delivery of the current expected standard of resuscitative care. This model also makes it difficult to plan for surges in blood product use without maintaining substantial stocks and thus the potential for wastage.
An alternative model for provision of blood in austere environments has been the use of fresh, warm whole blood 26 . This relies on blood donations by members of the community at the time of transfusion. Fresh whole blood has the benefit of containing all of the appropriate component products and has not undergone prolonged storage with the associated deterioration of the product 27, 28 . Often referred to as the 'walking blood bank', it will likely remain an option under dire circumstances, but has several disadvantages 29 . The donor pool needs to be sufficiently large, there is risk of infectious disease transmission, graft versus host disease, the health of donors may be compromised and there is significant potential for administrative or laboratory error.
There has been an extensive search for blood substitutes, particularly cell-free haemoglobin including chemically treated human, bovine and genetically engineered products 30 . It would be ideal to have a universal blood substitute that negated the need for crossmatching and was devoid of both side-effects and special storage requirements. However, 30 years of investigations have failed to produce a safe alternative to the RBC 31, 32 . A recent meta-analysis demonstrated not only an increased mortality but a threefold increase in the incidence of myocardial infarction in those patients receiving synthetic RBC substitutes 33 .
Lyophilised plasma can be stored for 1.5 years at 2-25°C and is used by both German civilian and military hospitals 34 . The quality of fresh reconstituted lyophilised plasma is comparable to thawed -80°C plasma, which has been stored for seven days at 4°C 35 . A recent study evaluated clotting factor and inhibitor activity in reconstituted lyophilised plasma after storage for up to six days at 2-6°C and found the coagulation factors, activity met required quality standards 36 . Although lyophilised platelets are under development, they are not yet ready for clinical trials 37 .
Cryopreserved blood products
Cryopreservation is the process of preserving the biologic structure and/or function of living systems by freezing and storage at low temperatures. As with standard refrigeration, cryopreservation uses the beneficial effect of decreased temperature to suppress molecular motion and arrest biochemical reactions. To take advantage of the protective effects of low temperature and to successfully store RBCs and platelets for extended periods using cryopreservation techniques, damage during freezing and thawing must be minimised 38 . The current hypothesis is that cryoinjury is a combination of excessive cellular dehydration, osmotic injury and the injurious effects of intra and extracellular ice crystal formation 38 .
Extensive work has demonstrated that cryoinjury is a function of the rate of cooling, the rate of warming and the cryopreservant used. Too slow or too rapid cooling during freezing and/or thawing results in greater cell injury 38, 39 .
To date, deep freezing is the only technique available to substantially extend the shelf life of blood products required for effective haemostatic resuscitation strategies and hence allow for the provision of these products in remote environments 37, 38, [40] [41] [42] [43] [44] . When frozen at -80°C, the shelf life is extended to ten years for red cells, seven years for deep frozen plasma (DFP) and two years for platelets 29, 45 .
The Netherlands military blood bank (MBB) has produced frozen red cells for use in military hospitals abroad since 1995, with frozen platelets and plasma provided since December 2001 [46] [47] [48] . In Afghanistan during the period from 2006-2012, they transfused 6246 units that had been frozen and stored at -80°C (2175 red cell units, 3001 DFP units and 1070 platelet units) with no reported transfusion reactions 46 .
RED BLOOD CELL CRyOPRESERVATION
The cryoprotective effects of glycerol on red cells have been known for more than 50 years 49, 50 . Glycerol is a cryoprotectant that readily permeates into cells at 37°C. The advantage of using glycerol is that it is relatively non-toxic at high concentrations and can be used for freezing at -80°C. In contrast, other cryoprotectants such as hydroxyethylstarch and polyvinylpyrrolidone, require liquid nitrogen for freezing 38, 51 . Glycerol protects cells from freezing injury by penetrating the cell and replacing intracellular water without causing excessive cellular volume reduction, as well as lowering the temperature at which electrolytes form lethal salt concentrations 38 . Glycerol also acts to depress the freezing point 38 and modifies the thermodynamic properties of the liquid 52 , thus reducing the amount of ice crystal formation. Therefore, despite exposure to -80°C, the erythrocytes do not incur significant osmotic stress and are not damaged by ice crystal formation. Two glycerol based methods for cryopreservation have been described 38, 53 . The first employs a low glycerol concentration (15-20%) with rapid cooling (~100°C/minute) achieved with liquid nitrogen to a final temperature of -196°C 54 . The second method uses a higher glycerol concentration (40%) with slow cooling (∼1°C/minute) to a final temperature of -80°C 55 . Although the low glycerol method appears to produce a higher recovery after thaw, the cells are less stable and more susceptible to post-thaw storage haemolysis 53 .
Since liquid nitrogen is highly impractical to transport and to maintain in austere environments, the Netherlands MBB employs the high glycerol, slow cooling technique 53 which was further improved by the introduction of a sterile processing method 56, 57 . This technique is also employed by the Australian Red Cross Blood Service to preserve rare phenotype red cells. Each unit of leukodepleted whole blood is centrifuged and the remaining RBCs in plasma (with a haematocrit of 80%) are mixed with 57% weight/volume glycerol to a final concentration of 40%. The glycerol is infused using an automated cell processor (ACP-215 Haemonetics, Braintree, MA, USA) which provides a sterile, closed system ( Figure 3 ).
The glycerolised unit is then centrifuged and excess glycerol in the supernatant is removed. The final product (40% glycerol and 60% haematocrit) is then frozen to a temperature of -80°C on the bottom of an empty -80°C mechanical freezer at a rate of approximately 1-3°C/minute.
Prior to transfusion the deep frozen RBCs need to be thawed and processed. Post-thaw removal of glycerol is essential to prevent post-transfusion intravascular haemolysis 53 . The deep frozen RBC unit is thawed in a temperature-controlled water bath at 37°C. To produce a transfusible product, the glycerol is removed (deglycerolisation) in a closed sterile system with the ACP-215 cell washer.
The cells are diluted with a 12% sodium chloride solution (Baxter, Deerfield, IL, USA), followed by several washes with a 0.9% sodium chloride and 0.2% glucose solution (Baxter, Deerfield, IL, USA). After washing, the deglycerolised red cells are resuspended in additive solution 3 (Haemonetics, Braintree, MA, USA) ( Table 2) .
Thawing and washing the RBCs in preparation for transfusion takes approximately 100 minutes. If the product is not immediately required for transfusion, it may be stored for 14 days at 2-6°C 45 .
PLATELET CRyOPRESERVATION
Dimethyl sulfoxide (DMSO) is used as a cryoprotectant to prevent cell death during the freezing process and has been extensively used to protect platelets from cryoinjury 51, 58 . Current cryopreservation strategies focus on minimising the damaging actions of physicochemical stressors and membrane disruption associated with extra and intracellular ice formation that occurs in cells during the freeze-thaw process. Ice crystal formation occurs as a result of the freezing process, which can puncture the plasma membrane, leading to cell death. DMSO protects the cells by partially solubilising the membrane so that it is less prone to puncture and interrupting the lattice of the ice so that fewer crystals can form 59 (Figure 4 ). Fresh, leukodepleted apheresis platelet concentrates are infused with 27% DMSO in 0.9% saline to a final concentration of 4-6% in plasma. The platelet unit, with the added DSMO, is then centrifuged such that the majority of the supernatant containing the DMSO and plasma are removed. The DMSO treated, concentrated platelet unit is then packed in a vacuum sealed overwrap, packed in a cardboard box and frozen on the bottom of an empty -80°C freezer to a temperature of -80°C at a rate of 3-5°C/ minute. When required for transfusion, the platelets are warmed to 30-32°C in a temperature-controlled water bath maintained at 37°C. This thawing process takes approximately five minutes. The thawed platelets are resuspended in thawed DFP and are then suitable for transfusion. Post-thaw removal of DMSO is not required as most is removed by centrifugation and supernatant extraction prior to freezing. Each platelet unit should contain less than 10 g of DMSO.
The maximum recommended dose of DMSO is 1 g/kg of recipient body weight. Above this dose, adverse reactions such as headache, nausea and vasoconstriction would be expected to occur 60 . Noorman et al demonstrated, in their evaluation of more than a thousand platelet units (n=1189), that the thawed product quality is constant and is independent of the thawing location (3.0±0.6×10 11 platelets/unit; 0.7±0.2 g DMSO/unit; volume 313±15 ml and freeze-thaw recovery 74±12%) 47 . The in vitro ability of the thawed DFPs to initiate and form a thrombus is satisfactory. The Netherlands MBB has shown that alterations to the platelet phenotype result in more rapid initiation of in vitro thrombogenesis but with reduced clot strength using thromboelastography and a higher content of activated platelets and microparticles using flow cytometry 47 . Similarly, frozen platelets resuspended in platelet additive solution or DFP have reduced aggregation and are activated in vitro and resuspension in plasma resulted in a higher freeze-thaw recovery 61 . These phenotypic changes are comparable with the changes reported by Valeri et al of cryopreserved platelets resuspended in saline or plasma 39, 59, 62 . Further, a double-blinded clinical trial in 73 cardiopulmonary bypass patients has demonstrated that thawed cryopreserved platelets more effectively facilitated haemostasis in post-surgical bleeding compared to liquid stored platelets 63 . Dumont et al have recently conducted a randomised, phase I study comparing 6% DMSO cryopreserved platelets versus autologous fresh platelet viability and in vitro function in healthy subjects. They showed in vivo recovery and survival of cryopreserved platelets may be comparable to some platelets currently in clinical use 61 . The accumulating evidence suggests that thawed frozen platelets are activated and generate thrombus more quickly than non-frozen platelets, thereby indicating that DFPs are highly effective in haemostasis 62, 64, 65 .
DEEP FROZEN PLASMA
The production of DFP is not complex. Leukodepleted apheresis AB RhD positive fresh-frozen plasma is initially thawed from -30-30°C (to facilitate transport and ensure quarantine compliance). Following thawing, the fresh-frozen plasma is repacked, relabelled and deep frozen to -80°C at a rate of 1-3°C/minute 45 . This process extends the shelf life of plasma from one year at -30°C to seven years at -80°C. Furthermore, this DFP can be stored and conveniently transported with the other deep frozen blood products ( Figure 5 ). Prior to transfusion, the DFP units must be thawed for 25-35 minutes in a 37°C temperature-controlled water bath to 30-35°C. The quality of DFP has been assessed, with coagulation factor concentrations well preserved following thawing and subsequent storage at 2-6°C for up to seven days 37, 66 . The Dutch reported on the safety of DFP from their Afghanistan experience, where 3001 units of plasma were transfused without a single adverse transfusion reaction 48 .
Experience with frozen blood products
During the cold war, concerns for the potentially massive casualty rates saw the British Army maintain a -196°C frozen RBC inventory in Germany 67 . In Western Australia in the 1970s, a -196°C frozen supply of erythrocytes was maintained 68 and, as with many first world countries 69 , the Australian Red Cross Blood Service currently has an inventory of rare phenotype -80°C frozen red cells. The Netherlands Red Cross Blood Bank (now called Sanquin) established a -196°C frozen red cell bank in 1962, which effectively still serves as the Council of Europe's frozen blood repository 67 . In 2005 Sanquin switched to the -80°C method. The United States of America used the -80°C technology as far back as the 1960s, making use of frozen RBCs in the Vietnam conflict 70 . The Netherlands military have used -80°C frozen red cells since 1995 and -80°C frozen platelets and plasma since December 2001 for military hospitals abroad [45] [46] [47] [48] .
SAFETy OF FROZEN BLOOD PRODUCTS
The absence of transfusion reactions encountered by the Netherlands military with deep frozen products may be related to the safety measures employed. First, only leukodepleted products are used. Second, all cellular products are frozen within 24 hours of donation, thus ensuring the highest possible quality after thawing. Third, the apheresis platelets are monitored for bacterial contamination using the BacT/Alert (BioMeuriuex) system. Importantly only male plasma donations are used to produce both frozen and DFP with the intention of decreasing the incidence of transfusion-related acute lung injury 71, 72 . The Netherlands Red Cross Blood Bank has demonstrated a 33% reduction of transfusion-related acute lung injury 71 through the use of male-only -30°C frozen plasma 73 .
POTENTIAL APPLICATIONS OF CRyOPRE-SERVED PRODUCTS

Military
The applicability to the military setting is obvious and highly viable. Military operations, including humanitarian missions in the South Pacific region, could potentially be enhanced by a frozen blood product capability. A very plausible hypothetical situation is one where the Australian Defence Force is tasked to provide healthcare to victims of a cyclone or tsunami. A Royal Australian Navy ship with a full surgical capability deploys to the affected area 3000 nautical miles away. At the current time, a limited supply of refrigerated blood (shelf life of at best 40 days) could be embarked. Frozen plasma could be provided and there would be no viable way to depart with a supply of liquid platelets.
The requirement for massive blood transfusion is even more pronounced in the setting of penetrating or battlefield trauma. Current literature from the Afghanistan and Iraq conflicts report that as many as 15% of casualties require massive transfusions (>10 units in 24 hours) and that the mortality in this group is 20-50% 18, 29, 74, 75 . Where reliable and regular resupply of refrigerated products is potentially compromised, frozen products provide an excellent alternative for deployed isolated forces. The equipment and training capability is easily achievable.
Transportation of frozen blood products has been effectively achieved by the Netherlands military in shipping containers with dry ice allowing for up to 5-7 days (small containers) and 7-14 days (large containers) transit time, depending on the volume of dry ice added and environmental conditions without exceeding the maximum storage and transport temperature of -65°C. During their mission in Afghanistan (2006-2012) only ten units of frozen red cells were discarded due to temperature breaches during transport 48 .
The Naval Blood Research Laboratory in the United States of America has demonstrated a relatively low incidence of breakage with human RBCs cryopreserved by the same method employed by the Netherlands MBB with subsequent storage at -80°C for 14-18 years. In 2366 non-transported cryopreserved units, stored at -80°C for up to 18 years, there was only a 2.4% breakage rate and for 633 units that underwent transportation at some stage in their 14 year storage the breakage rate was 6.7% 76 48 .
Regional Australia
Australia is a highly developed country of vast dimensions, with many small, isolated regional hospitals. There are many centres in regional and remote Australia where it is not possible for the attending clinician to prescribe and transfuse individual blood components. Certainly platelets are not routinely available to the acutely bleeding patient, with the only current alternative being transfusion of fresh whole blood. With the technology readily available to produce frozen blood products and international research demonstrating the excellent quality of these products, it is prudent to consider their use in Australia. The partially automated process for thawing of red blood cells, the rapid and relatively unsophisticated techniques for the thawing of platelets and plasma makes this both a practical and viable solution for geographically remote locations. The Australian Red Cross Blood Service is currently working towards supplying deep frozen blood products for use by the Australian Defence Force. Protocols for freezing and thawing red cells, plasma and platelets at -80°C have been adapted to suit the blood collection and processing requirements in Australia, based on those used by the Netherlands MBB 77 . The adoption of this technology in Australia has great potential and in the future may provide a solution to some of the problems associated with supplying blood across such a vast geographical region.
LIMITATIONS OF FROZEN BLOOD PRODUCTS
There are several limitations associated with the use of these products. Once deep frozen blood products are deployed to a regional hospital, humanitarian mission or war zone, they need to be managed in a 'peripheral blood bank'. This requires specialised equipment, expertise, ongoing quality assurance and training. One of the significant drawbacks is the time required to thaw RBCs prior to their use. A single unit takes approximately 100 minutes to prepare, but remains viable for at least 14 days when stored in the appropriate additive solution at 2-6°C. In practice, several automated cell processors are required and ideally product thawing should commence prior to anticipated use.
The financial cost of production of frozen products to the point of transfusion is significant, but where no viable alternative exists, this cost may be justifiable.
A further possible issue for the implementation of frozen blood products is the requirement for approval by the relevant regulatory authorities. Frozen RBCs are approved by the United States Food and Drug Authority, have long been used for rare phenotypes in civilian practice and are also approved for use in Australia. The use of frozen platelets has been approved by the Netherlands military and the German Civilian Paul Ehrlich Institute for use in bleeding (military) trauma patients in emergency situations when no fully-tested liquid-stored platelets are available. Although 1082 units have been transfused in 333 patients without any transfusion reaction reported 46 , a multicentre effectiveness or non-inferiority trial should be performed prior to the introduction of cryopreserved platelets into general clinical practice in Australia. If a frozen blood product capability were to be adopted by the Australian Defence Force, or indeed be used in the Australian civilian arena, approval for its use would need to be sought and granted by the Australian Therapeutic Goods Administration (TGA). This agency is responsible for regulating therapeutic goods including medicines, medical devices, blood and blood products. The TGA also regulates manufacturers of therapeutic goods to ensure they meet acceptable standards of manufacturing quality. The Australian Red Cross Blood Service is regularly audited by the TGA and adheres to Good Manufacturing Practice guidelines. Frozen blood products would be subject to the same rigorous standards. If Australian hospitals were approved to thaw frozen blood products, it is likely that they would require a TGA licence and ongoing accreditation from an agency such as Australia's National Laboratory Accreditation Authority, which recognises and promotes facilities competent in specific types of testing, measurement, inspection and calibration. The Australian and New Zealand Society of Blood Transfusion would also likely be involved and potentially publish guidelines for the use of frozen products not dissimilar to those currently available for standard blood products.
CONCLUSIONS
The development of effective -80°C cryopreservation techniques for RBCs, platelets and plasma, which maintains ex vivo biological activity, provides an attractive blood banking strategy. This technology greatly enhances the storage life of vital products and makes the provision of these products in remote environments far more reliable. This review has demonstrated that the technology is readily available and has been comprehensively tested in austere military settings producing excellent results. We believe an integrated fresh-frozen blood bank inventory could facilitate the provision of products to regional Australia, overcoming the logistical and geographical challenges of supplying blood products to these environments. The subsequent improvement in the delivery of acute care, by virtue of the ability to provide appropriate blood products, at the appropriate time could possibly save Australian lives.
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